Sensorium shares Phase 1a trial results
SNTX-2643 showed reduced blood levels by 24 hours, yet exploratory findings indicated a lingering difference in brain response to stress compared to placebo.
Latest Sensorium Therapeutics News & Updates
See the latest news and media coverage for Sensorium. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing nature-derived CNS therapies
sensorium.bio- Headquarters
- Boston, United States
- Founded year
- 2021
- Company type
- Private company
- Number of employees
- 25–50
- Industry
- Pharmaceuticals
Last updated
Latest news about Sensorium Therapeutics (Sensorium)
In short: Sensorium reported positive Phase 1a SNTX-2643 data, including exploratory brain-response differences versus placebo.
Company announcements
Sensorium appoints Charles Nemeroff to advisory board
Dr. Nemeroff joins to guide clinical testing of SNTX-2643, a differentiated serotonin transporter mechanism for brain and mental health conditions.
Sensorium adds Dr Sanjay Mathew to Clinical Advisory Board
He will evaluate rapid-acting psychiatric therapeutics for anxiety disorders using SNTX-2643.
Sensorium receives FDA IND clearance for SNTX-2643
The first-in-class anxiolytic is a precision serotonin modulator, with first-in-human dosing in Q3 2025.
Media coverage
Sensorium Therapeutics Announces Positive Phase 1a Data for SNTX-2643 Showing Rapid and Sustained CNS Pharmacodynamic Activity
Beta is faster-frequency brain activity associated with an alert and actively processing cortical state, while delta is slower-frequency activity that becomes more prominent in lower-arousal...
Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced that Phase 1a...
Sensorium Therapeutics Receives FDA IND Clearance for SNTX-2643, a First-in-Class, Rapid-Acting Anxiolytic
BOSTON, July 8, 2025 /PRNewswire/ -- Sensorium Therapeutics, Inc. (Sensorium), a neuroscience therapeutics company inspired by nature and guided by human biology to transform mental...
Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines
BOSTON, Nov. 8, 2022 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company leveraging medicinal chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for...
Never miss news about Sensorium
Track Sensorium and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Sensorium competitors & trending companies
Browse news for competitors to Sensorium and other trending companies.
Clene
Biogen
Neurizon
BioArctic
Prilenia
Nura Bio
Revalesio
QurAlis
Alzinova
Herantis Pharma
Saniona
VectorY
Mitochon
NRG Therapeutics
Celosia
NeuroSense
Ophidion
AL-S Pharma
Sironax
CervoMed
Filana Therapeutics
Alector
UCB
NRx
Axoltis
Neurimmune
Raya
Vaalco
Prominence
Trident Energy
MOL
Beacon Offshore Energy
Meren
Cantium
Kosmos
Tullow